ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Core Insights - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 11:15 a.m. ET [1] - A webcast of the fireside chat will be available on the company's investor website, with a replay accessible for 90 days post-event [2] Company Overview - ORIC Pharmaceuticals is dedicated to improving patients' lives by overcoming resistance in cancer [3] - The company's clinical stage product candidates include ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for various genetically defined cancers [3] - ORIC has offices located in South San Francisco and San Diego, California [3]